A Phase 3 interventional study of Placebo and Nalmefene in Alcohol Dependence, sponsored by H. Lundbeck A/S. Completed at 57 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.
Among the 12 studies testing nalmefene in Alcoholism, this one has the largest enrollment, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 3rd registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →
nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2009.
This study's enrollment of 678 is above the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 212 across the 12 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 6 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 6 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing nalmefene in Alcoholism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.
Alcohol dependence is a maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested by at least three of a number of criteria such as tolerance, withdrawal symptoms, frequent use of alcohol in larger amounts or over longer periods than was intended, and others. Excessive intake of alcohol reduces the life span by a decade, and alcohol drinking is strongly related to mortality from liver cirrhosis, chronic pancreatitis, certain cancers, hypertension, accidents and violence. This study is planned to evaluate the efficacy and safety of as needed use of nalmefene 18.06 mg versus placebo in decreasing monthly Heavy Drinking Days (HDDs) and decreasing the total consumption during a period of 24 weeks in adult patients with alcohol dependence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In- and outpatients who:
Exclusion Criteria:
The patient:
Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Nalmefene
as-needed use, tablets, orally, 6 months
18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Also known as: Selincro™
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.
Time frame: Baseline and Month 6
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
Time frame: Baseline and Month 6
Drinking Risk Level (RSDRL) Response
RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.
Time frame: Month 6
Change From Baseline in Clinical Status Using CGI-S
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
Time frame: Baseline and Week 24
Change in Clinical Status Using the CGI-I
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Week 24
Liver Function Test Gamma-glutamyl Transferase (GGT)
GGT values
Time frame: Week 24
Liver Function Test Alanine Aminotransferase (ALAT)
ALAT values
Time frame: Week 24
| Milestone | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Started | 360 | 358 |
| Completed | 337 | 341 |
| Not completed | 23 | 17 |
| Withdrew: Did not receive placebo/nalmefene | 23 | 17 |
| Milestone | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Started | 337 | 341 |
| Completed | 205 | 194 |
| Not completed | 132 | 147 |
| Withdrew: Adverse event | 8 | 15 |
| Withdrew: Lack of efficacy | 13 | 7 |
| Withdrew: Non-compliance | 6 | 9 |
| Withdrew: Protocol violation | 36 | 27 |
| Withdrew: Withdrawal by subject | 45 | 54 |
| Withdrew: Lost to follow-up | 11 | 14 |
| Withdrew: Other reason | 13 | 21 |
Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.
| days | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) | -10.58 ± 0.52 | -12.30 ± 0.54 |
TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
| g | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Change From Baseline in the Monthly Total Alcohol Consumption (TAC) | -54.06 ± 2.23 | -59.01 ± 2.29 |
RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.
| percentage of participants | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Drinking Risk Level (RSDRL) Response | 47.9 | 45.6 |
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Change From Baseline in Clinical Status Using CGI-S | -1.04 ± 0.08 | -1.27 ± 0.08 |
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| units on a scale | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Change in Clinical Status Using the CGI-I | 2.68 ± 0.08 | 2.51 ± 0.08 |
GGT values
| IU/L | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Liver Function Test Gamma-glutamyl Transferase (GGT) | 44.9 ± 75.7 | 43.3 ± 75.2 |
ALAT values
| IU/L | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Liver Function Test Alanine Aminotransferase (ALAT) | 27.2 ± 56.3 | 25.0 ± 55.7 |
Collected over Serious Adverse Events: 24 weeks, a 4-week run-out period, and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 24 weeks and a 4-week run-out period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 14/337 (4.2%) | 102/337 (30.3%) |
| Nalmefene 18.06 mg | — | 7/341 (2.1%) | 157/341 (46%) |
| Event | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| Intentional overdoseInjury, poisoning and procedural complications | 3/337 | 0/341 |
| AlcoholismPsychiatric disorders | 0/337 | 2/341 |
| Pancreatitis acuteGastrointestinal disorders | 1/337 | 0/341 |
| Rectal haemorrhageGastrointestinal disorders | 1/337 | 0/341 |
| PneumoniaInfections and infestations | 1/337 | 0/341 |
| PyothoraxInfections and infestations | 1/337 | 0/341 |
| Subcutaneous abscessInfections and infestations | 1/337 | 0/341 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/337 | 0/341 |
| Alcohol poisoningInjury, poisoning and procedural complications | 1/337 | 0/341 |
| Drug toxicityInjury, poisoning and procedural complications | 1/337 | 0/341 |
| Event | Placebo | Nalmefene 18.06 mg |
|---|---|---|
| NauseaGastrointestinal disorders | 20/337 | 59/341 |
| DizzinessNervous system disorders | 14/337 | 52/341 |
| InsomniaPsychiatric disorders | 23/337 | 49/341 |
| HeadacheNervous system disorders | 26/337 | 43/341 |
| NasopharyngitisInfections and infestations | 20/337 | 22/341 |
| VomitingGastrointestinal disorders | 8/337 | 19/341 |
| DiarrhoeaGastrointestinal disorders | 18/337 | 8/341 |
| AnxietyPsychiatric disorders | 17/337 | 11/341 |
| Age Continuous(years) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| Mean | 44.4 ± 10.7 | 45.1 ± 10.7 | 44.8 ± 10.7 |
| Sex: Female, Male(Participants) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| Female | 104 | 92 | 196 |
| Male | 256 | 266 | 522 |
| Previously Treated for Alcohol Dependence(participants) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| NO | 213 | 215 | 428 |
| YES | 147 | 142 | 289 |
| UNKNOWN | 0 | 1 | 1 |
| Previously Treated for Alcohol Withdrawal Symptoms](participants) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| NO | 292 | 300 | 592 |
| YES | 68 | 57 | 125 |
| UNKNOWN | 0 | 1 | 1 |
| Total Monthly Heavy Drinking Days (HDD)(days) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| Mean | 18.37 ± 7.03 | 19.71 ± 6.96 | 19.04 ± 7.03 |
| Total Alcohol Consumption (TAC) g Alcohol/Day(g) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| Mean | 88.76 ± 48.15 | 92.22 ± 46.87 | 90.49 ± 47.52 |
| Drinking Risk Level (DRL)(participants) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| Low | 6 | 5 | 11 |
| Medium | 82 | 68 | 150 |
| High | 134 | 129 | 263 |
| Very High | 138 | 156 | 294 |
| Clinical Global Impression - Severity of Illness (CGI-S)(units on a scale) | Placebo | Nalmefene 18.06 mg | Total |
|---|---|---|---|
| Mean | 3.99 ± 1.42 | 4.05 ± 1.45 | 4.02 ± 1.44 |
2 further baseline measures are reported on the registry.
The record gives a start of Mar 2009, a primary completion of Mar 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene